https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19323
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADFamotidine by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of velpatasvir .
Possible decrease of clinical efficacy.
Monitor for clinical efficacy.
–
–
Administrer at the same time and/or 12 hours after the combined drug.
Recommended dosage : dose not exceeding famotidine 40 mg twice daily or equivalent.
–
–
–
Reference number |
---|
# patients |
HCV |
Dose |
Frequency |
AUC |
Cmax |
3379 | 3379 |
---|---|
35 | 36 |
- | - |
400/100/100 mg | 400/100/100 mg |
x 1 | x 1 |
- 6%/- 10%/- 2% † | - 13%/- 15%/- 6% †† |
- 4%/- 9%/- 10% † | - 7%/- 13%/- 10% †† |
3379 | 3379 |
---|---|
35 | 36 |
- | - |
40 mg | 40 mg |
x 1 * | x 1 ** |
Ref #3379 : * At the same time as sofosbuvir/velpatasvir/voxilaprevir;
† GS-331007 : AUC +4%; Cmax +8%;
** 12 hours after sofosbuvir/velpatasvir/voxilaprevir;
†† GS-331007 : AUC +1%; Cmax +14%.